The influence of genetic ancestry and ethnicity on breast cancer survival associated with genetic variation in the TGF-β-signaling pathway: The Breast Cancer Health Disparities Study

[1]  H. Putter,et al.  The prognostic role of TGF-β signaling pathway in breast cancer patients. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  R. Wolff,et al.  Genetic variation in genes involved in hormones, inflammation and energetic factors and breast cancer risk in an admixed population. , 2012, Carcinogenesis.

[3]  G. Stein,et al.  Runx2 mediates epigenetic silencing of the bone morphogenetic protein-3B (BMP-3B/GDF10) in lung cancer cells , 2012, Molecular Cancer.

[4]  Joshua F. McMichael,et al.  Whole Genome Analysis Informs Breast Cancer Response to Aromatase Inhibition , 2012, Nature.

[5]  S. Choe,et al.  BMPs and their clinical potentials. , 2011, BMB reports.

[6]  C. López-Camacho,et al.  The Runx transcriptional co-activator, CBFβ, is essential for invasion of breast cancer cells , 2010, Molecular Cancer.

[7]  B. Komm,et al.  Genome-Wide Analysis of Estrogen Receptor α DNA Binding and Tethering Mechanisms Identifies Runx1 as a Novel Tethering Factor in Receptor-Mediated Transcriptional Activation , 2010, Molecular and Cellular Biology.

[8]  A. Kallioniemi,et al.  Bone morphogenetic proteins in breast cancer: dual role in tumourigenesis? , 2010, Endocrine-related cancer.

[9]  Gretchen L. Gierach,et al.  Expression of TGF-β signaling factors in invasive breast cancers: relationships with age at diagnosis and tumor characteristics , 2010, Breast Cancer Research and Treatment.

[10]  P. Rosenberg,et al.  Pathway analysis by adaptive combination of P‐values , 2009, Genetic epidemiology.

[11]  R. Derynck,et al.  TGFβ family signaling: novel insights in development and disease , 2009, Development.

[12]  W. Jiang,et al.  Bone morphogenetic proteins in development and progression of breast cancer and therapeutic potential (review). , 2009, International journal of molecular medicine.

[13]  A. Kallioniemi,et al.  BMP7 influences proliferation, migration, and invasion of breast cancer cells. , 2009, Cancer letters.

[14]  R. Mansel,et al.  Reduced expression of BMPR-IB correlates with poor prognosis and increased proliferation of breast cancer cells. , 2009, Cancer genomics & proteomics.

[15]  Charles M. Perou,et al.  Triple-Negative Breast Cancer: Risk Factors to Potential Targets , 2008, Clinical Cancer Research.

[16]  H. Doihara,et al.  Bone morphogenetic protein 6 (BMP6) and BMP7 inhibit estrogen-induced proliferation of breast cancer cells by suppressing p38 mitogen-activated protein kinase activation. , 2008, The Journal of endocrinology.

[17]  K. Miyazono,et al.  Bone morphogenetic protein signaling enhances invasion and bone metastasis of breast cancer cells through Smad pathway , 2008, Oncogene.

[18]  D. Katsaros,et al.  TGF-β1 genotype and phenotype in breast cancer and their associations with IGFs and patient survival , 2008, British Journal of Cancer.

[19]  Jun Du,et al.  Bone morphogenetic protein 6 inhibit stress‐induced breast cancer cells apoptosis via both smad and P38 pathways , 2008, Journal of cellular biochemistry.

[20]  Gerard C Blobe,et al.  Role of transforming growth factor-beta superfamily signaling pathways in human disease. , 2008, Biochimica et biophysica acta.

[21]  K. Rieger,et al.  A 25-year single institution experience with surgery for primary mediastinal nonseminomatous germ cell tumors. , 2008, The Annals of thoracic surgery.

[22]  W. Jiang,et al.  Bone morphogenetic proteins and their receptor signaling in prostate cancer. , 2007, Histology and histopathology.

[23]  Vassilios Vassiliou,et al.  Prognostic significance of TGFbeta-1 and pSmad2/3 in breast cancer patients with T1-2,N0 tumours. , 2007, Anticancer research.

[24]  R. Wolff,et al.  Body size, weight change, fat distribution and breast cancer risk in Hispanic and non-Hispanic white women , 2007, Breast Cancer Research and Treatment.

[25]  G. Stein,et al.  Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone , 2006, Cancer and Metastasis Reviews.

[26]  C. Knabbe,et al.  TGF‐Beta Signaling in Breast Cancer , 2006, Annals of the New York Academy of Sciences.

[27]  Bogomir Dimitrijević,et al.  Elevated plasma TGF-beta1 levels correlate with decreased survival of metastatic breast cancer patients. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[28]  M. Thun,et al.  Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort , 2006, Breast Cancer Research.

[29]  S. Romain,et al.  Determination of TGFβ1 protein level in human primary breast cancers and its relationship with survival , 2006, British Journal of Cancer.

[30]  E. John,et al.  Migration History, Acculturation, and Breast Cancer Risk in Hispanic Women , 2005, Cancer Epidemiology Biomarkers & Prevention.

[31]  Lei Z. Zhang,et al.  Activation of bone morphogenetic protein-6 gene transcription in MCF-7 cells by estrogen. , 2005, Chinese medical journal.

[32]  Karen Blyth,et al.  The runx genes: gain or loss of function in cancer , 2005, Nature Reviews Cancer.

[33]  A. Harris,et al.  Bone morphogenetic protein 2 (BMP-2) induces in vitro invasion and in vivo hormone independent growth of breast carcinoma cells. , 2004, International journal of oncology.

[34]  P. Fritz,et al.  Prognostic Significance of Transforming Growth Factor β Receptor II in Estrogen Receptor-Negative Breast Cancer Patients , 2004, Clinical Cancer Research.

[35]  E. John,et al.  Lifetime physical activity and breast cancer risk in a multiethnic population: the San Francisco Bay area breast cancer study. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[36]  J. Swan,et al.  Cancer rates among American Indians and Alaska Natives , 2003, Cancer.

[37]  Motomi Osato,et al.  RUNX and cancer. , 2003, Annals of the Academy of Medicine, Singapore.

[38]  M. Stephens,et al.  Inference of population structure using multilocus genotype data: linked loci and correlated allele frequencies. , 2003, Genetics.

[39]  K. Blyth,et al.  The Runx genes as dominant oncogenes. , 2003, Blood cells, molecules & diseases.

[40]  S. Bae,et al.  Both the Smad and p38 MAPK pathways play a crucial role in Runx2 expression following induction by transforming growth factor-β and bone morphogenetic protein , 2002, Oncogene.

[41]  P. Donnelly,et al.  Inference of population structure using multilocus genotype data. , 2000, Genetics.

[42]  J. Samet,et al.  Reproductive risk factors for breast cancer in Hispanic and non-Hispanic white women: the New Mexico Women's Health Study. , 1998, American journal of epidemiology.

[43]  G. Stein,et al.  Metastatic bone disease: role of transcription factors and future targets. , 2011, Bone.

[44]  W. Zheng.  Genetic polymorphisms in the transforming growth factor-beta signaling pathways and breast cancer risk and survival. , 2009, Methods in molecular biology.

[45]  I. Lacreuse,et al.  Conflict of Interest: None , 2009 .

[46]  M. Salto‐Tellez,et al.  RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression , 2008, Breast Cancer Research and Treatment.

[47]  R. Hayes,et al.  Cancer Causes & Control , 2004, Cancer Causes & Control.